Shares in RxSight Inc. are up 11% to $9.82 on preliminary fourth quarter results and the announcement of a new chief financial officer.
Fourth quarter revenue is expected to be $32.6 million, coming in above the $27.5 million expected by analysts. Full year revenue is expected to be $134.5 million, exceeding the company’s previously announced guidance of $125 million to $130 million.
“Despite headwinds in 2025, our team made meaningful progress, enabling us to treat more patients than ever before,” Chief Executive Ron Kurtz said in a statement.
The Aliso Viejo-based cataract lens maker also appointed Mark Wilterding CFO, succeeding Shelley Thunen, who is stepping down nearly a decade at the company. See the Jan. 5 edition for an interview with Thunen.
Wilterding is said to have more than 25 years of financial leadership experience at medtech companies, having most recently served as senior vice president of global finance at Edwards Lifesciences Corp. and director of investor relations at Medtronic prior to Edwards.
RxSight said it will announce fourth quarter and full year financial results sometime next month.
